Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
13 nov. 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 oct. 2019 09h08 HE
|
Autolus Therapeutics plc
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Tymidinkinas 1 kan användas för tidigt terapisvar vid behandling av bröstcancer
18 sept. 2019 11h10 HE
|
AroCell AB
Patienter behandlade med Epirubicin och Docetaxel före operationen följdes med deras tymidinkinas (TK1) nivåer i blodet för att direkt observera behandlingssvaret. Resultaten visar att en TK1-baserat...
Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment
18 sept. 2019 11h10 HE
|
AroCell AB
Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based...
AroCell AB (publ) Delårsrapport 1 januari – 30 juni 2019
21 août 2019 02h00 HE
|
AroCell AB
VD-ORD ”Det är med glädje som jag kan konstatera att det andra kvartalet 2019 blev ett av det mest spännande och aktiva kvartal i AroCells historia. Målet att etablera AroCell som den givne partnern...
AroCell AB (publ) Interim Report January 1st to June 30th 2019
21 août 2019 02h00 HE
|
AroCell AB
Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as...
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
20 août 2019 13h17 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....
AroCell tecknar ett nytt distributörsavtal i USA och Kanada
06 août 2019 02h15 HE
|
AroCell AB
AroCell AB (publ) meddelade idag att man har tecknat ett distributionsavtal med Diapharma Group i West Chester Ohio för marknadsföring och distribution av AroCell TK 210™ ELISA i USA och Kanada. ...
AroCell signs a new distributor agreement in the USA and Canada
06 août 2019 02h15 HE
|
AroCell AB
AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United...
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
07 juil. 2019 20h00 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...